anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: The role of SMU1 in DNA replication and RNA splicing is well-established, yet its specific function and dysregulated mechanisms in gastric cancer (GC) remain inadequately elucidated. This study seeks to investigate the potential oncogenic and progression-promoting effects of SMU1 in GC, with the ultimate goal of informing novel approaches for treatment and diagnosis.
METHODS: The study investigated the expression levels of SMU1 in GC and adjacent normal tissues by analyzing data from the TCGA (27 tissue pairs) and GEO (47 tissue pairs) databases. Immunohistochemistry was used to examine 277 tumor tissue and adjacent non-tumor tissue spots from GC tissue chips, along with relevant follow-up information. The study further assessed the proliferation, invasion, and migration capabilities of cells by manipulating SMU1 expression levels and conducting various assays, including CCK-8, EdU incorporation, colony formation, transwells, flow cytometry, and subcutaneous tumorigenesis assays.
RESULTS: Our study revealed a significant upregulation of SMU1 mRNA and protein levels in GC tissues compared to adjacent tissues. Univariate and multivariate Cox analysis demonstrated that elevated levels of SMU1 were independent prognostic factors for GC prognosis (P = 0.036). Additionally, median survival analysis indicated a significant association between high SMU1 expression and poor prognosis in GC patients (P = 0.0002). In experiments conducted both in vivo and in vitro, it was determined that elevated levels of SMU1 can enhance the proliferation, invasion, and migration of GC cells, whereas suppression of SMU1 can impede the progression of GC by modulating the G1/S checkpoint of the cell cycle.
CONCLUSIONS: Our research introduces the novel idea that SMU1 could serve as a prognostic marker for GC progression, influencing cell proliferation through cell cycle activation. These results offer valuable insights into the understanding, diagnosis, and management of gastric carcinoma.
PROBLEM TO BE SOLVED: To prepare a suppressant for the formation of bacterial plaques, greatly improved in suppressing effects on the formation of the bacterial plaques, having high safety and hardly affecting the taste of a composition by using a glucan hydrolase with a specific organic phosphoric acid compound in combination. SOLUTION: This suppressant for bacterial plaques is prepared by using a phytic acid represented by the formula or its salt (M is a cation derived from H, an alkali metal or an amine) and a glucan hydrolase in combination. The amount of the formulated phytic acid represented by the formula or its salt is 0.01-10 wt.% based on the whole composition. Dextranase, mutanase, cariogenanase, etc., can be cited as the glucan hydrolase. The amount thereof formulated is 100-50,000 units based on 1 g composition for the oral cavity in the case of, e.g. the dextranase and 10-10,000 units in the case of, e.g. the mutanase.
BACKGROUND: Adiposity shows opposing associations with mortality within COVID-19 versus non-COVID-19 respiratory conditions. We assessed the likely causality of adiposity for mortality among intensive care patients with COVID-19 versus non-COVID-19 by examining the consistency of associations across temporal and geographical contexts where biases vary.
METHODS: We used data from 297 intensive care units (ICUs) in England, Wales, and Northern Ireland (Intensive Care National Audit and Research Centre Case Mix Programme). We examined associations of body mass index (BMI) with 30-day mortality, overall and by date and region of ICU admission, among patients admitted with COVID-19 (N = 34,701; February 2020-August 2021) and non-COVID-19 respiratory conditions (N = 25,205; February 2018-August 2019).
RESULTS: Compared with non-COVID-19 patients, COVID-19 patients were younger, less often of a white ethnic group, and more often with extreme obesity. COVID-19 patients had fewer comorbidities but higher mortality. Socio-demographic and comorbidity factors and their associations with BMI and mortality varied more by date than region of ICU admission. Among COVID-19 patients, higher BMI was associated with excess mortality (hazard ratio (HR) per standard deviation (SD) = 1.05; 95% CI = 1.03-1.07). This was evident only for extreme obesity and only during February-April 2020 (HR = 1.52, 95% CI = 1.30-1.77 vs. recommended weight); this weakened thereafter. Among non-COVID-19 patients, higher BMI was associated with lower mortality (HR per SD = 0.83; 95% CI = 0.81-0.86), seen across all overweight/obesity groups and across dates and regions, albeit with a magnitude that varied over time.
CONCLUSIONS: Obesity is associated with higher mortality among COVID-19 patients, but lower mortality among non-COVID-19 respiratory patients. These associations appear vulnerable to confounding/selection bias in both patient groups, questioning the existence or stability of causal effects.
A randomized, open-label, active-controlled study evaluated the efficacy of 10 weeks of treatment with two different daily dosing regimens of ENDOMETRIN (100 mg twice daily and 100 mg three times daily) for support of implantation and early pregnancy in infertile women participating in an Assisted Reproductive Technology treatment program. Efficacy was assessed on the endpoint of ongoing pregnancies, defined as the presence of at least one fetal heartbeat seen on ultrasound at 6 weeks post-embryo transfer. The study randomized to ENDOMETRIN 808 infertile women (74.9% White; 10.3% Hispanic, 5.4% Black, 5% Asian, and 4.6% Other) between 19 and 42 years of age (mean age 33) who had a body mass index <34 kg/m2 at screening.

The ongoing pregnancy rates for subjects treated with both dosing regimens of ENDOMETRIN were non-inferior (lower bounds of the 95% confidence interval of the difference between ENDOMETRIN and the active comparator excluded a difference greater than 10%) to the ongoing pregnancy rate for subjects treated with the active comparator. The results of this study are shown in Table 3.

Subjects participating in the study were stratified at randomization by age and ovarian reserve (as measured by serum FSH levels). The ongoing pregnancy rates for these subgroups are shown in Table 4.

In subjects under the age of 35 or with serum FSH levels less than 10 IU/L, results from both dosing regimens were non-inferior to the results from the comparator with respect to ongoing pregnancy rates. In women age 35 and older and in women with serum FSH levels between 10 and 15 IU/L, the results with respect to ongoing pregnancy rates for both dosing regimens of ENDOMETRIN did not reach the criteria for non-inferiority.

Subjects who became pregnant received study medication for a total of 10 weeks. Patients over 34 kg/m2 were not studied. The efficacy of ENDOMETRIN in this patient group is unknown.
This vaccine injection contains all the same components of Arm C and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player witnesses the sharing of an opioid prescription within their family. This storyline includes information about medication safety and opioid overdose identification and response.
INTRODUCTION: Chronic pain is a common complication after surgery and trauma. The incidence of chronic pain may potentially be reduced by effective management of severe acute pain, in hospital and during the subacute post-operative phase at home.
METHODS: This was a cohort study from an outpatient follow-up service for patients with pain at discharge after orthopaedic surgery and trauma in a level 1 university hospital setting. The patients' charts were reviewed. Demographics, diagnosis and treatment were registered. The objective of this study was to describe the first five years of experience with this service.
RESULTS: A total of 261 patients were included. The median age was 39 (interquartile range (IQR): 26-76) years, and 53% were men. The median pain duration was ten (IQR: 5-22) months. Neuropathic pain was diagnosed in 83% of patients. Complex regional pain syndrome was diagnosed in 10% and suspected in 8%. Before the consultation, 48% were using paracetamol and/or non-steroid anti-inflammatory drugs (NSAIDs), 25% opioids, and 36% used gabapentioids or antidepressants. After their consultation, only 13% used paracetamol and/or NSAIDs and 8% opioids, whereas 86% were treated with gabapentinoids or antidepressants. A plan for opioid weaning was provided for all patients if opioids were continued (8%).
CONCLUSIONS: Establishing an outpatient pain service for persistent pain after surgery and trauma may encourage the use of analgesia regimens that are in accordance with international guidelines and ensure that opioids are not continued inappropriately.
FUNDING: None.
TRIAL REGISTRATION: Not relevant.
Children and adolescents with rheumatic diseases can experience significant disability in both the short and long term due to pain, muscle weakness, fatigue, and restricted joint movement. Exercise training has been noted to potentially benefit individuals with pediatric rheumatic diseases by alleviating various clinical symptoms related to physical disability. In this regard, it is important to routinely assess and monitor physical inactivity and sedentary behaviors, along with examining behaviors that may hinder or facilitate physical activity. However, no tool has been encountered to assess behaviors that may hinder or facilitate physical activity in individuals with pediatric rheumatic disease. In this sense, the importance of examining physical activity barriers and facilitators in children with rheumatic disease is clear. The Inflammatory Arthritis Facilitators and Barriers to Physical Activity (IFAB) questionnaire was developed to assess perceived facilitators and barriers to physical activity in patients with inflammatory arthritis. For this purpose, the validity and reliability of the IFAB questionnaire in individuals with pediatric rheumatic diseases (juvenile idiopathic arthritis, juvenile fibromyalgia syndrome, juvenile dermatomyositis) will be examined. Under the supervision of a physical therapist, participants will be assessed using the IFAB questionnaire to evaluate perceived facilitators and barriers to physical activity, the Fear Avoidance Beliefs Questionnaire - Physical Activity (FABQ-PA) questionnaire for fear-avoidance beliefs, and the Motivation Scale For Participation In Physical Activity (MSPPA) to measure motivation for physical activity participation. The results of the IFAB questionnaire will be utilized in the validity and reliability analysis, as well as in the analysis of construct validity. For reliability analysis, the IFAB questionnaire will be repeated after 7 days. All forms will be sent to children in Google form format. It is planned to include 70 children in this study. Factor analysis methods will be used in the analysis of the factor structure of the scale, correlation analyses (Pearson and Spearman coefficients) will be used in the analysis of validity and test-retest reliability. Cronbach's alpha analysis will be used in the reliability analysis. The study will be the first to examine physical activity barriers and facilitators in Turkish children with rheumatic disease. The results will contribute to the identification of physical activity barriers and facilitators in Turkish children with rheumatic diseases.
The present invention relates to an antioxidant-1 (Atox1) which controls homeostasis of copper and is called as HAH1. The Atox1 has an antioxidant protection function for protecting cell from toxicity generated by superoxide anion and peroxide. But, a biological function of Atox1 in forebrain ischemic stroke is unknown. Inventors have found that Atox1 fusion protein has an ischemic stroke animal model protection effect in in vivo and a cell protection effect on the destruction of neuron due to oxidation stress in in vitro. The Atox1 fusion protein is efficiently permeated depending on concentrate and time into the neuron and increases a cell survival rate on the toxicity of peroxide. The Atox1 reduces DNA fragmentation due to the peroxide and activated oxygen in the cell and shows a protection effect on the destruction of the neuron caused when a temporary ischemia is caused at a CA1 part of forebrain hippocampus in an animal model. According to the results, the Atox1 fusion protein has a protection effect on the destruction of the cell and a curing effect for protecting neuron from the damage to the ischemia.
Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with glyburide tablets or any other anti-diabetic drug.

Hypoglycemia: All sulfonylureas including glyburide are capable of producing severe hypoglycemia. Proper patient selection and dosage and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may cause elevated drug levels of glyburide and the latter may also diminish gluconeogenic capacity, both of which increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose lowering drug is used. The risk of hypoglycemia may be increased with combination therapy.

Loss of Control of Blood Glucose: When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection or surgery, a loss of control may occur. At such times it may be necessary to discontinue glyburide tablets and administer insulin.

The effectiveness of any hypoglycemic drug, including glyburide tablets, in lowering blood glucose to a desired level decreases in many patients over a period of time which may be due to progression of the severity of diabetes or to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when glyburide tablets is first given. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure.
Laparoscopic surgery has become an acceptable alternative for open surgery in treating benign gynecologic diseases. One of most important advantages of laparoscopy is a reduced postoperative pain compared with open surgery. Moreover, postoperative pain plays an important part in the enhanced recovery after surgery (ERAS) pathway. Although the length of hospitalization and recovery period after laparoscopy tends to be shorter, postoperative pain can still be an important issue.

Recently, continuous wound infusion (CWI) providing a constant flow of local anesthetic directly a surgical wound postoperatively has been widely used to reduce pain after cesarean section and open surgery. Studies evaluating the effectiveness of CWI to manage postoperative pain following laparoscopy are markedly lacking. Especially, there was no study comparing CWI and placebo in treating gynecologic laparoscopy. Therefore, the investigators conducted this randomized, double-blind, placebo-controlled trial to investigate whether CWI of local anesthetics was an effective strategy for ERAS, compared with placebo in patients undergoing benign gynecologic laparoscopy.
PURPOSE:To provide a dentifrice composition having excellent light resistance, and resistant to discoloration even in a container having a transparent part to enable the transmission of sun light, by coloring a dentifrice with a heat-resistant tar pigment and filling the dentifrice in a container having a transparent part. CONSTITUTION:A colored dentifrice composition colored with a light-resistant tar pigment such as Food Red 106, Food Red 2, Food Yellow 4, etc., and filled in a transparent container. At least a part of the container has a visible light transmittance of >=50%. When a filler (preferably titanium dioxide) is added to the above composition in an amount of 0.001-5wt% of the whole composition, the light resistance can be improved remarkably without lowering the beautiful appearance of the dentifrice, and the containing composition can be filled suitably in a transparent container having a clear part with an ultraviolet transmittance of as high as >=5%. Even a transparent container wherein the ultraviolet transmission of the transparent container wherein the ultraviolet transmission of the transparent part is >=3% may be used effectively, however, it is preferable to keep the transmittance to <=30% to prevent the discoloration of the perfumery, binder, etc. of the dentifrice composition.
A swab comprising a handling element ( 1 ), at least at one end with a tip ( 2 ) made of an absorbent material. The tip ( 2 ) is impregnated with a make-up removing composition and shaped such that it has at least one apex ( 6 ). The make-up removing solution may be an eye make-up removing composition. The tip may be shaped in the shape of a triangle. The handling element ( 1 ) may be a stick made of polymeric materials or wood and connected to the tip ( 2 ) such that at least one side ( 4 ) and one vertex of the triangle are positioned opposite to the handling element ( 1 ). The swabs are packaged.
Complication of third stage of labor in second trimester medical pregnancy termination is not well studied. Accord to publications, the placental retention rate is 30 to 40% in these situations. Placental retention may be associated with increased blood loss, increased requirement for blood transfusion anesthetic and operative complications, and infectious morbidity. The high incidence of retained placenta is an area of clinical concern. Publications reveal a wide variation in practices but there are only few studies about third stage of labor in second trimester medical pregnancy termination. The study is a prospective randomized trial. Two third stage management strategies are compared: 10 units of intra venous oxytocin (group 1) and no additional medication (group 2) after fetal expulsion. It concerns pregnancies between 14 and 28 weeks gestation.
The external plaster for treating baby's heat cough is developed based on the pathological features and the pathological cause of baby's heat cough. It is prepared with 17 kinds of Chinese medicinal materials including forsythia, sweet wormwood herb, skullcap root, bitter orange, etc. and through decoction, concentration, crushing, mixing and other steps. The external plaster for treating baby's heat cough has the functions of dispelling wind, clearing away heat, promoting lung-Qi flow, eliminating phlegm, etc. and is used mainly for treating baby's heat cough caused by different reasons. The medicine has convenient use and obvious effect, and the preparation process is suitable for industrial production.
A method, a computer program product, and a computer system initiate an exercise sequence on an exercise-integrated workstation. A set of active monitored activities is identified. A set of preferences and goals for the exercise sequence is identified. A set of accumulated details regarding any user modifications to previous exercise sequences is identified. A set of scheduled events is identified. Responsive to identifying the set of active monitored activities, the set of preferences and goals, the set of accumulated details, and the set of scheduled events, the method determines whether to initiate an exercise sequence. Responsive to determining to initiate the exercise sequence, the method initiates the exercise sequence.
The invention relates to a method for preparing a traditional Chinese medicine Pinellia ternate, comprising the following steps of: taking crude Pinellia ternate and placing in a closed container, adding the ethanol solution with volume by volume concentration of 65-80% to soak for 24-48 hours, then drying to obtain prepared Pinellia ternate. In the invention, the ethanol solution with volume by volume concentration of 65-80% is used for soaking Pinellia ternate, and the ethanol solution has stronger penetrating power for plant cells and acrimony of Pinellia ternate so that the acrimony of the Pinellia ternate can be obviously reduced after being soaking for 24-48 hours. Tested by toxicologic experiment, the prepared Pinellia ternate is acrimony free and does not numb the tongue. In the method of soaking Pinellia ternate, ethanol is less used, and only 20-30% of the weight of crude Pinellia ternate is needed to detoxicate. In the invention, alum is not used, thereby avoiding poison of A1<3+> intake of excessive residue on nervous system during the preparation of auxiliary material alum and ensuring safe clinic use. The invention meanwhile solves the problem of component loss caused by long-term soaking in water or boiling and mouldy deterioration of Pinellia ternate caused by long-term soaking in water in hot weather. The invention can effectively ensure safe and effective clinic use of Pinellia ternate.
Techniques are disclosed for preparing a repeat intervention on the skin of a patient. This may include acquiring first image data of an intervention region during a first intervention on the skin of the patient. At least two landmarks may be identified on the skin of the patient on the basis of the acquired first image data. A position of the first intervention is then determined with the aid of the landmarks as reference points. In addition, the position of the first intervention and of the landmarks may be stored in a data memory unit. A position of the second intervention is subsequently localized on the basis of the stored position and of the at least two landmarks.
Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
1. The use of leptin or a leptin homologue or derivative thereof optionally together with an inhibitor of VEGF action or of VEGF synthesis and/or an inhibitor of angiogenesis, in the preparation of a medicament reversibly inhibiting endothelial cell proliferation. 2. The use according to claim 1, including an angiogenesis inhibitor. 3. The use according to anyone of the preceding claims wherein the VEGF inhibitor is selected from DMPX, an A2-antagonist 7- (beta-hydroxyethyl) theophylline, 8-phenyltheophylline, the adenosine A2 receptor antagonist CSC, theobromine, an antagonistic VEGF variant, sFLT-1, Tranilast, 8-(3-oxo-4,5,6-trihydroxy-3h-xanthen-9-yl)-1-naphthoic acid, suramin and platelet factor-4. 4. A pharmaceutical composition for reversibly inhibiting endothelial cell proliferation comprising leptin or a leptin homologue or derivative thereof optionally together with an inhibitor of VEGF action or of VEGF synthesis and/or an inhibitor of angiogenesis. 5. A method for reversibly inhibiting endothelial cell proliferation in mammals comprising administering to a subject a pharmaceutical composition according to claim 4 in a suitable dosage form and by a suitable route of administration. 6. A mixture for use in angiogenesis inhibiting comprising leptin and a VEGF inhibitor.